Omega Diagnostics Gp (ODX.L) Speculation regarding a potential fundraise

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products.

Notes the recent online speculation and confirms that it is in discussions with certain investors and shareholders regarding a potential equity fundraising.

Market conditions remain challenging and accordingly any issue of equity would be at a discount to the current share price. Any fundraise would include an open offer to accommodate retail investors.

As per the announcement of 19 January, the Company has significant cash resources. Accordingly, there is no immediate need to raise additional capital and the Company may choose not to proceed with fundraising until such time as conditions are more favourable.

A further announcement will be made in due course as necessary.


Omega Diagnostics Group PLC

Jag Grewal, Chief Executive Officer

via Walbrook PR

Chris Lea, Chief Financial Officer

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned


Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.